RxDoctor Payments DataLook up a doctor →

Terrence Bradley, MD

Hematology · Miami, FLNPI 1134495021

Payments from drug & device makers

$636,622in general payments, 2019–2025

Across 633 payments — averaging $1005.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$299K
  • Incyte Corporation$125K
  • AbbVie$61K
  • Otsuka Pharmaceutical Co., Ltd.$58K
  • Sumitomo Pharma America, Inc.$31K
  • Novartis$26K
  • plus $37K from 22 others
$30in research payments, 2019–2025

Across 1 payment — averaging $29.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$30

What the payments were for

  • Consulting fees$35,62067%
  • Speaking & faculty fees$8,25016%
  • Travel & lodging$5,47010%
  • Food & beverage$3,5947%
  • Education$780%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$636,622 in reported general payments places this provider in the 85th percentile of 79 hematology providers in Florida.

See all hematology providers in Florida

Medicare billing

Part B allowed, 2024
$53,167
Medicare patients
90
Services billed
423

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IdhifaEnasidenib Mesylate13$447,049
OjjaaraMomelotinib Dihydrochloride13$361,818
InrebicFedratinib Dihydrochloride13$316,534
VonjoPacritinib Citrate12$293,217
JakafiRuxolitinib Phosphate20$273,766
ScemblixAsciminib Hydrochloride11$236,840
InqoviDecitabine/Cedazuridine28$221,718
VenclextaVenetoclax40$146,790
Imipenem-Cilastatin SodiumImipenem/Cilastatin Sodium11$6,938
XareltoRivaroxaban12$6,283
Hydroxyurea20$404
Acyclovir15$207
Ondansetron Hcl14$118
Doxazosin Mesylate11$84

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbIdhifa, Inrebic$86$763,58226 claims
Incyte CorporationJakafi$125,376$273,76620 claims
NovartisScemblix$25,596$236,84011 claims
AbbVieVenclexta$60,626$146,79040 claims
Johnson & JohnsonXarelto$12$6,28312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 79 hematology providers in Florida.

Other hematology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →